Prevention of preterm labour: 2011 update on tocolysis

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Reproductive Medicine

Background:

• Preterm labor is a leading cause of neonatal morbidity and mortality.
• Tocolytic therapy aims to delay birth, allowing for interventions to improve fetal outcomes.
• A comprehensive understanding of available tocolytic agents is crucial for clinical decision-making.

Purpose of the Study:

• To review and synthesize available data on drugs used for preventing preterm labor.
• To analyze the efficacy, safety, and side effect profiles of various tocolytic agents for both mother and fetus.
• To discuss the indications and rationale for the administration of tocolysis.

Main Methods:

• Systematic literature review of pharmacological agents used in preterm labor prevention.
• Analysis of studies reporting on myometrial contractility, maternal and fetal safety, and treatment efficacy.
• Discussion of clinical guidelines and evidence-based practices for tocolytic therapy.

Main Results:

• Tocolytic therapy encompasses a range of drug classes including beta-adrenergic agonists, nitric oxide donors, magnesium sulfate, prostaglandin-synthase inhibitors, oxytocin receptor antagonists, calcium-channel blockers, progesterone, and antibiotics.
• Each drug class exhibits distinct mechanisms affecting myometrial contractility.
• Data on maternal and fetal safety, efficacy, and side effects vary significantly across different tocolytic agents.

Conclusions:

• The choice of tocolytic agent requires careful consideration of efficacy, safety, and specific clinical context.
• Further research is needed to optimize tocolytic strategies and minimize adverse effects.
• Understanding the indications for tocolysis is paramount for appropriate patient management.